Loading...
NPI 1962852889 · Brentwood, MO · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Avinash Honasoge is a retina specialist (ophthalmology) physician provider located in Brentwood, Missouri. This profile covers 16 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Avinash Honasoge |
| Address | 1600 S Brentwood Blvd Ste 700 |
| City | Brentwood |
| State | MO |
| ZIP | 63144 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | June 22, 2016 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.7M |
| Medicaid | $480 |
AVINASH HONASOGE is enumerated as an NPI since 2016-06-22 (~10 years ago) and is listed as a Retina Specialist (Ophthalmology) Physician practicing in BRENTWOOD, MO. The tenure and taxonomy align with a specialty practice focused on retina procedures and diagnostics rather than a general ophthalmology or multispecialty clinic. This longevity supports an established outpatient retina service line.
The provider’s Medicare revenue profile is dominated by intravitreal injection drugs and related procedures: J0178 (aflibercept) accounts for $1M (57.7% of Medicare revenue), J2777 (faricimab) accounts for $269.7K (15.5%), and J2778 (ranibizumab) accounts for $95.6K (5.5%). Together these three codes represent 78.8% of total Medicare revenue, indicating the practice’s primary business activity is high-volume therapeutic retina injections for macular disease.
Revenue concentration on Medicare is high: the precomputed top-3 Medicare codes drive 78.8% of the provider’s Medicare revenue, with a single drug code J0178 alone contributing $1M (57.7%). That concentrated mix signals material exposure to shifts in drug utilization, formulary changes, or reimbursement policy affecting anti-VEGF therapies.
Imaging and diagnostics are a clear operational focus: Medicare 92134 appears with 2.6K claims and $77.6K revenue (4.5% of Medicare revenue) and ranks #620 of 26868 providers nationally (98th percentile; extreme outlier). This unusually high national percentile for retinal imaging suggests the practice has substantial in‑office OCT capacity and relies heavily on diagnostic imaging to manage retina patients and support procedural throughput.
Office visit and E/M activity is above typical for peers: 99213 shows $53.4K (3.1% of Medicare revenue) and ranks in the 98th percentile nationally (notably above typical), while 99204 shows $34.8K (2.0%) and ranks in the 99th percentile (extreme outlier). These elevated E/M percentiles indicate significant new and established patient visit volume, consistent with a busy specialist clinic that combines evaluation with procedural services.
Competitive standing for the high-cost drug codes is modest rather than dominant: J0178 ranks #844 of 3204 providers (74th percentile; typical), J2777 ranks #1060 of 2039 (48th percentile; typical), and J2778 ranks #693 of 1208 (43th percentile; typical). In plain terms, the provider is an active, routine-volume injector nationally but not a top regional or national leader for these specific drug codes.
Payer mix is heavily skewed to Medicare: total Medicare revenue is $1.7M compared with total Medicaid revenue of $478, so Medicare constitutes virtually all billed revenue on file and the provider is effectively a Medicare-focused practice. The Medicaid claims that do exist are concentrated entirely in retinal imaging: Medicaid 92134 shows 27 claims and $486 revenue and is listed as 100.0% of the provider’s Medicaid code revenue, and that Medicaid 92134 ranking is #55 of 62 in-state (11th percentile; typical).
From a business-risk and opportunity perspective, the profile is that of a retina practice whose economics are driven by anti-VEGF administration and high-throughput imaging. The reliance on J0178 ($1M) and two other injection codes (combined 78.8% of Medicare revenue) creates both operational scale advantages for procedure throughput and sensitivity to drug-pricing, payer policy, or shifts toward alternative therapies or settings of care.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 1,470 | $680 | $1M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 9,300 | $30 | $269.7K |
| J2778 | Injection, ranibizumab, 0.1 mg | 540 | $180 | $95.6K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 970 | $90 | $89.8K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,590 | $30 | $77.6K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 650 | $90 | $58K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 840 | $60 | $53.4K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 290 | $120 | $34.8K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 280 | $100 | $26.4K |
| 67042 | In this procedure, the provider removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical cutting tool. He removes the internal limiting membrane of the retina… | 10 | $880 | $11.4K |
Showing 1–10 of 16
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 16 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
16 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 12 | 60 | 820 | $690 | $683.3K |
| J2777 | 26 | 50 | 11,730 | $30 | $388.9K |
| J2778 | 12 | 20 | 540 | $180 | $203.8K |
| 67028 | 23 | 80 | 600 | $90 | $69.7K |
| 67042 | 26 | 30 | 20 | $1,070 | $26.8K |
| J9035 | 27 | 40 | 170 | $60 | $21.8K |
| 92014 | 60 | 730 | 120 | $80 | $18K |
| 99214 | 1,840 | 8,960 | 100 | $80 | $13.9K |
| 99213 | 115 | 8,730 | 70 | $50 | $7K |
| 92134 | 11 | 570 | 60 | $30 | $6.8K |
Showing 1–10 of 16
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 30 | $20 | $490 |
How this provider's Medicaid billing volume and revenue compare to other Missouri providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Missouri median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 55 | 60 | 340 | $20 | $19.3K |
Other providers in the same ZIP code as Avinash Honasoge, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Pyramid Homemaker Services, Inc. | MO | In Home Supportive Care Agency | $0 | $15.7M |
| Heeral Shah | MO | Retina Specialist (Ophthalmology) Physician | $1.6M | $0 |
| Sam Martin | MO | Interventional Pain Medicine Physician | $34.1K | $1.3M |
| Thomas Krummenacher | MO | Retina Specialist (Ophthalmology) Physician | $737.7K | $280 |
| Empowerme Diagnostics LLC | MO | Clinical Medical Laboratory | $271.9K | $0 |
| Rachel Darken | MO | Neurology Physician | $221.4K | $0 |
| Luqi Chi | MO | Neurology Physician | $137.3K | $0 |
| Craig Sorce | MO | Optometrist | $101.8K | $0 |
| Kelsey Melsheimer | MO | Occupational Therapist | $83.1K | $0 |
| Samir Cardona | MO | Physical Therapist | $79.7K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.